

Supplementary Table 1. Characteristics of included studies, total sample size, patients lost to follow-up and reported p-values.

Study drug, trial	Design	Arm	Sample size	Patients lost to follow-up/withdrawn	Reported p-value	FI	RFI
Abatacept, NCT00430677	Double-blind, parallel-group, multicenter (85 sites).	Abatacept, 30/10	298	25	0.806*	--	9
		Abatacept, 10/10	99	23	0.48*	--	7
		Placebo	100	22			
Anifrolumab, TULIP-1	Double-blind, parallel-group, multicenter (123 sites, 18 countries).	Anifrolumab, 300mg	457	36	0.412	--	27
		Placebo	180	38			
			184				
Anifrolumab, TULIP-2	Double-blind, parallel-group, multicenter (119 sites, 16 countries).	Anifrolumab, 300mg	365	27	0.001	11	--
		Placebo	180	52			
			182				
Atacicept, APRIL-SLE	Double-blind, parallel-group, multicenter (125 sites)	Atacicept, 75mg	461	45	0.543	--	13
		Placebo	159	43			
			157				
Baricitinib, SLE-BRAVE-I	Double-blind, parallel-group, multicenter (182 sites, 18 countries)	Baricitinib, 2mg	769	56	0.47	--	15
		Baricitinib, 4mg	258	55	0.016	4	--
		Placebo	254	68			
			257				
Baricitinib, SLE-BRAVE-II	Double-blind, parallel-group, multicenter (162 sites, 15 countries)	Baricitinib, 2mg	778	55	0.79	--	22
		Baricitinib, 4mg	262	62	0.71	--	19
		Placebo	259	49			
			257				
Belimumab, BLISS-52	Double-blind, parallel-group, multicenter (90 sites, 13 countries)	Belimumab, 10mg/kg	867	49	0.0006	17	--
		Placebo	290	61			
			287				

Study drug, trial	Design	Arm	Sample size	Patients lost to follow-up/withdrawn	Reported p-value	FI	RFI																																																																																										
Belimumab, BLISS-76	Double-blind, parallel-group, multicenter (136 sites, 19 countries)	Belimumab, 10mg/kg	819 273	82	0.017	4	--																																																																																										
		Placebo	275	89				Belimumab, BLISS-SC	Double-blind, parallel-group, multicenter (177 sites, 30 countries)	Belimumab, 200mg SC	836 556	93	0.0006	16	--	Placebo	280	66	Belimumab, BEL113750	Double-blind, parallel-group, multicenter (49 sites, 3 countries)	Belimumab, 10mg/kg	707 451	82	<0.0001	15	--	Placebo	226	56	Belimumab, BLISS-LN	Double-blind, parallel-group, multicenter (107 sites, 21 countries)	Belimumab, 10mg/kg	448 223	76	0.03	3	--	Placebo	223	91	Blisibimod, CHABLIS-SC1	Double-blind, parallel-group, multicenter (15 countries)	Blisibimod	442 245	53	0.352	--	13	Placebo	197	44	Epratuzumab, EMBODY1	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	793 248	94	0.442	--	14	Epratuzumab 1200mg Q2W	244	81	0.175	--	9	Placebo	249	90				Epratuzumab, EMBODY2	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	791 266	82	0.716	--	18	Epratuzumab 1200mg Q2W	262	91	0.899	--	21	Placebo	263	85				Rituximab, EXPLORER	Double-blind, parallel-group, multicenter (55 sites)	Rituximab	257 169	49	0.886*
Belimumab, BLISS-SC	Double-blind, parallel-group, multicenter (177 sites, 30 countries)	Belimumab, 200mg SC	836 556	93	0.0006	16	--																																																																																										
		Placebo	280	66				Belimumab, BEL113750	Double-blind, parallel-group, multicenter (49 sites, 3 countries)	Belimumab, 10mg/kg	707 451	82	<0.0001	15	--	Placebo	226	56	Belimumab, BLISS-LN	Double-blind, parallel-group, multicenter (107 sites, 21 countries)	Belimumab, 10mg/kg	448 223	76	0.03	3	--	Placebo	223	91	Blisibimod, CHABLIS-SC1	Double-blind, parallel-group, multicenter (15 countries)	Blisibimod	442 245	53	0.352	--	13	Placebo	197	44	Epratuzumab, EMBODY1	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	793 248	94	0.442	--	14	Epratuzumab 1200mg Q2W	244	81			0.175	--	9	Placebo	249	90				Epratuzumab, EMBODY2	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	791 266	82	0.716	--	18	Epratuzumab 1200mg Q2W			262	91	0.899	--	21	Placebo	263	85				Rituximab, EXPLORER	Double-blind, parallel-group, multicenter (55 sites)	Rituximab	257 169	49	0.886*	--	20	Placebo	88	24		
Belimumab, BEL113750	Double-blind, parallel-group, multicenter (49 sites, 3 countries)	Belimumab, 10mg/kg	707 451	82	<0.0001	15	--																																																																																										
		Placebo	226	56				Belimumab, BLISS-LN	Double-blind, parallel-group, multicenter (107 sites, 21 countries)	Belimumab, 10mg/kg	448 223	76	0.03	3	--	Placebo	223	91	Blisibimod, CHABLIS-SC1	Double-blind, parallel-group, multicenter (15 countries)	Blisibimod	442 245	53	0.352	--	13	Placebo	197	44	Epratuzumab, EMBODY1	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	793 248	94	0.442	--	14	Epratuzumab 1200mg Q2W	244	81			0.175	--	9	Placebo	249	90				Epratuzumab, EMBODY2	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	791 266	82	0.716	--	18	Epratuzumab 1200mg Q2W	262	91			0.899	--	21	Placebo	263	85				Rituximab, EXPLORER	Double-blind, parallel-group, multicenter (55 sites)	Rituximab	257 169	49	0.886*	--	20	Placebo	88	24													
Belimumab, BLISS-LN	Double-blind, parallel-group, multicenter (107 sites, 21 countries)	Belimumab, 10mg/kg	448 223	76	0.03	3	--																																																																																										
		Placebo	223	91				Blisibimod, CHABLIS-SC1	Double-blind, parallel-group, multicenter (15 countries)	Blisibimod	442 245	53	0.352	--	13	Placebo	197	44	Epratuzumab, EMBODY1	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	793 248	94	0.442	--	14	Epratuzumab 1200mg Q2W	244	81			0.175	--	9	Placebo	249	90				Epratuzumab, EMBODY2	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	791 266	82	0.716	--	18	Epratuzumab 1200mg Q2W	262	91			0.899	--	21	Placebo	263	85				Rituximab, EXPLORER	Double-blind, parallel-group, multicenter (55 sites)	Rituximab	257 169	49	0.886*	--	20	Placebo	88	24																								
Blisibimod, CHABLIS-SC1	Double-blind, parallel-group, multicenter (15 countries)	Blisibimod	442 245	53	0.352	--	13																																																																																										
		Placebo	197	44				Epratuzumab, EMBODY1	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	793 248	94	0.442	--	14	Epratuzumab 1200mg Q2W	244	81			0.175	--	9	Placebo	249	90				Epratuzumab, EMBODY2	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	791 266	82	0.716	--	18	Epratuzumab 1200mg Q2W	262	91			0.899	--	21	Placebo	263	85				Rituximab, EXPLORER	Double-blind, parallel-group, multicenter (55 sites)	Rituximab	257 169	49	0.886*	--	20	Placebo	88	24																																			
Epratuzumab, EMBODY1	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	793 248	94	0.442	--	14																																																																																										
		Epratuzumab 1200mg Q2W	244	81	0.175	--	9																																																																																										
		Placebo	249	90																																																																																													
Epratuzumab, EMBODY2	Double-blind, parallel-group, multicenter	Epratuzumab 600mg QW	791 266	82	0.716	--	18																																																																																										
		Epratuzumab 1200mg Q2W	262	91	0.899	--	21																																																																																										
		Placebo	263	85																																																																																													
Rituximab, EXPLORER	Double-blind, parallel-group, multicenter (55 sites)	Rituximab	257 169	49	0.886*	--	20																																																																																										
		Placebo	88	24																																																																																													

Study drug, trial	Design	Arm	Sample size	Patients lost to follow-up/withdrawn	Reported p-value	FI	RFI																																																									
Rituximab, LUNAR	Double-blind, parallel-group, multicenter (52 sites)	Rituximab	144	7	0.55	--	16																																																									
		Placebo	72	18				Tabalumab, ILLUMINATE-1	Double-blind, parallel-group, multicenter	Tabalumab 120mg Q2W	1138	82	0.409	--	17	Tabalumab 120mg Q4W	381	87	0.052	--	4	Placebo	378	95				Tabalumab, ILLUMINATE-2	Double-blind, parallel-group, multicenter	Tabalumab 120mg Q2W	1124	77	0.002	15	--	Tabalumab 120mg Q4W	372	87	0.041*	2	--	Placebo	376	88				Ustekinumab, LOTUS	Double-blind, parallel-group, multicenter (140 sites, 20 countries)	Ustekinumab	516	155	1.00*	--	22	Placebo	308	103	Voclosporin, AURORA-1	Double-blind, parallel-group, multicenter (142 sites, 27 countries)	Voclosporin	357	15	<0.001
Tabalumab, ILLUMINATE-1	Double-blind, parallel-group, multicenter	Tabalumab 120mg Q2W	1138	82	0.409	--	17																																																									
		Tabalumab 120mg Q4W	381	87	0.052	--	4																																																									
		Placebo	378	95																																																												
Tabalumab, ILLUMINATE-2	Double-blind, parallel-group, multicenter	Tabalumab 120mg Q2W	1124	77	0.002	15	--																																																									
		Tabalumab 120mg Q4W	372	87	0.041*	2	--																																																									
		Placebo	376	88																																																												
Ustekinumab, LOTUS	Double-blind, parallel-group, multicenter (140 sites, 20 countries)	Ustekinumab	516	155	1.00*	--	22																																																									
		Placebo	308	103																																																												
Voclosporin, AURORA-1	Double-blind, parallel-group, multicenter (142 sites, 27 countries)	Voclosporin	357	15	<0.001	15	--																																																									
		Placebo	179	31																																																												

*Not reported in original article. Two-sided Fisher's exact test.